# US 2008/0188550 A1 · Treatment of inflammation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0188550 A1
- Document ID: US20080188550A1
- Status: Published application
- Kind: A1
- Application number: 11/977,496
- Filed: 2007-10-25
- Published: 2008-08-07
- Earliest claimed: 1996-04-02
- Assignees: Mars, Incorporated
- Inventors: Kirk S. Kealey; Rodney M. Snyder; Leo J. Romanczyk; Hans M. Geyet; Mary E. Myers; Eric J. Whitacre; Harold H. Schmitz
- Web page: https://patentgrep.com/patent/US20080188550A1

## CPC

- C07H 17/06: Benzopyran radicals
- A23G 1/32: characterised by the composition {containing organic or inorganic compounds}
- A23G 3/36: characterised by the composition {containing organic or inorganic compounds}
- A23K 20/111: Aromatic compounds
- A23K 50/40: for carnivorous animals, e.g. cats or dogs
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2068: {Compounds of unknown constitution, e.g. material from plants or animals (oils, fats, waxes, shellac A61K9/2013)}
- A61K 9/4858: {Organic compounds}
- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 36/5777: {Theobroma, e.g. cocao or cocoa}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 311/32: 2,3-Dihydro derivatives, e.g. flavanones
- C07D 311/62: with oxygen atoms directly attached in position 3, e.g. anthocyanidins
- C07D 311/64: with oxygen atoms directly attached in position 8
- C11B 5/0035: {Phenols; Their halogenated and aminated derivates, their salts, their esters with carboxylic acids}
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A23G: COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23K: FODDER
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C11B: PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES (drying-oils C09F)

## Abstract

This invention relates to methods of treating inflammation comprising administering to a subject in need thereof a composition comprising the inventive compounds described herein.

## Claims

### Claim at position 1

1-208. (canceled)

### Claim 209

A method of treating inflammation in a subject in need thereof comprising administering to the subject a composition comprising an effective amount of at least one compound selected from the group of catechin, epicatechin, polymeric compounds of the formula An, a pharmaceutically acceptable salt thereof and an oxidation product thereof:
wherein
n is an integer from 2 to 18, such that there is at least one terminal monomeric unit A, and one or a plurality of additional monomeric units;
R is 3-(α)-OH, 3-(β)-OH, 3-(α)-O-sugar, or 3-(β)-O-sugar;
bonding between adjacent monomers takes place at positions selected from the group consisting of 4, 6 and 8;
a bond of an additional monomeric unit in position 4 has alpha or beta stereochemistry;
X, Y and Z are selected from the group consisting of monomeric unit A, hydrogen, and a sugar, with the proviso that as to the at least one terminal monomeric unit, bonding of the additional monomeric unit thereto is at position 4 and optionally Y=Z=hydrogen;
wherein the sugar is optionally substituted with a phenolic moiety;
wherein the subject is a human or a veterinary animal.

### Claim 210 (depends on 209)

The method of claim 209, wherein the compound is epicatechin.

### Claim 211 (depends on 210)

The method of claim 210 wherein the subject is a human.

### Claim 212 (depends on 209)

The method of claim 209, wherein the compound is a polymeric compound of the formula An wherein R is 3-(α)-OH or 3-(β)-OH, and X, Y and Z are selected from the group consisting of monomeric unit A or hydrogen.

### Claim 213 (depends on 212)

The method of claim 212, wherein the subject is a human.

### Claim 214 (depends on 213)

The method of claim 213, wherein n is 3 to 12.

### Claim 215 (depends on 212)

The method of claim 212, wherein the adjacent monomers bind at positions (4β→8).

### Claim 216 (depends on 212)

The method of claim 212, wherein the polymeric compound is selected from the group consisting of: dimer EC-(4β→8)-EC, dimer EC-(4β→6)-EC, trimer [EC-(4β→8)]2-EC, trimer [EC-(4β→6)]2-EC, tetramer [EC-(4β→8)]3-EC, pentamer [EC-(4β→8)]4-EC, and pentamer [EC-(4β→8)]3-EC-(4β→6)-EC, wherein EC is a monomeric unit epicatechin.

### Claim 217 (depends on 216)

The method of claim 216, wherein the subject is a human.

### Claim 218 (depends on 216)

The method of claim 216, wherein the subject is a veterinary animal.

### Claim 219 (depends on 210)

The method of claim 210, wherein the composition is a pharmaceutical composition.

### Claim 220 (depends on 210)

The method of claim 210, wherein the composition is a dietary supplement.
